Trial Profile
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Angina pectoris; Coronary artery disease
- Focus Therapeutic Use
- Acronyms TERISA
- Sponsors Gilead Sciences
- 26 Jul 2015 Results of a post hoc analysis published in the American Heart Journal.
- 20 Nov 2013 Results reporting QoL and disease-specific health status presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 19 Nov 2013 Results of an analysis according to baseline HbA1c levels presented at the 86th Annual Scientific Sessions of the American Heart Association.